Immune double plasma molecular adsorption system

Abstract

The present application discloses an immune double plasma molecular adsorption system, comprising: a first blood detection component, a blood pump component, a filtration pump component, a second blood detection component and an evaluation component. The first blood detection component is arranged on the arterial pipeline to detect the plasma content of the blood in the arterial pipeline; the blood pump component is arranged on the arterial pipeline to adjust the blood flow in the arterial pipeline according to the plasma content; the filtration pump component is arranged on the plasma branch to adjust the plasma flow in the plasma branch according to the blood chamber volume of the immunoadsorption column and the blood chamber volume of the hemoperfusion cartridge; the second blood detection component is arranged on the venous pipeline to detect the proportion of blood cells in the purified blood in the venous pipeline; the evaluation component is used to evaluate the blood purification effect of IDPMAS according to the ratio between the blood flow in the arterial pipeline and the plasma flow in the plasma branch and the proportion of blood cells. The present application can scientifically evaluate the blood purification effect of IDPMAS.

Description

Technical Field

[0001] This application relates to the technical field of blood purification, and particularly to an immune double plasma molecular adsorption system. Background Art

[0002] The immune double plasma molecular adsorption system (IDPMAS) is a new blood purification mode, which can achieve better clinical treatment effects in specific clinical symptoms. However, IDPMAS belongs to a completely new blood purification mode. During the process of clinical promotion and application, those skilled in the art cannot scientifically evaluate the blood purification effect of IDPMAS, thereby reducing the applicable scope of IDPMAS. Summary of the Invention

[0003] Based on this, this application provides an immune double plasma molecular adsorption system, which can scientifically evaluate the blood purification effect of the immune double plasma molecular adsorption system.

[0004] In a first aspect, this application provides an immune double plasma molecular adsorption system, which includes: an arterial line, a venous line, a plasma separator, a plasma branch, an immunoadsorption column, and a hemoperfusion cartridge; the blood input end of the plasma separator is connected to the arterial line, the blood output end of the plasma separator is connected to the venous line, the first end of the plasma branch is connected to the plasma output end of the plasma separator, and the second end of the plasma branch is connected to the venous line; the immunoadsorption column and the hemoperfusion cartridge are connected in series in the plasma branch in sequence; the system further includes:

[0005] A first blood detection component, arranged on the arterial line, for detecting the plasma content in the blood in the arterial line;

[0006] A blood pump component, arranged on the arterial line, for adjusting the blood flow in the arterial line according to the plasma content;

[0007] A filtration pump component, arranged on the plasma branch, for adjusting the plasma flow in the plasma branch according to the blood chamber volume of the immunoadsorption column and the blood chamber volume of the hemoperfusion cartridge;

[0008] A second blood detection component, arranged on the venous line, for detecting the proportion of blood cells in the purified blood output from the venous line;

[0009] An evaluation component, for evaluating the blood purification effect of the immune double plasma molecular adsorption system according to the ratio between the blood flow in the arterial line and the plasma flow in the plasma branch and the proportion of blood cells.

[0010] In the immune double plasma molecular adsorption system according to the embodiments of the present application, when performing double plasma adsorption on a patient's blood, the blood pump assembly adjusts the blood flow rate in the arterial line, and the filtration pump assembly adjusts the plasma flow rate in the plasma branch, so that both the blood flow rate in the arterial line and the plasma flow rate in the plasma branch can be maintained in an optimal state, which can improve the effect of double plasma adsorption on the patient's blood; and evaluate the blood purification effect of the immune double plasma molecular adsorption system according to the ratio between the blood flow rate in the arterial line and the plasma flow rate in the plasma branch and the proportion of blood cells, thereby establishing a scientific evaluation standard for evaluating the treatment effect of the IDPMAS treatment mode, facilitating the popularization and application of the IDPMAS treatment mode, increasing the applicable range of IDPMAS, and being beneficial to improving the control effect of the IDPMAS treatment mode.

[0011] It should be understood that the above general description and the following detailed description are only exemplary and explanatory, and cannot limit the present application. Brief Description of the Drawings

[0012] Figure 1 is a schematic diagram of the principle of an embodiment of the immune double plasma molecular adsorption system of the present application;

[0013] Figure 2 is a schematic diagram of the change curve of the liquid flow rate in the pipeline of the immune double plasma molecular adsorption system of the present application over time;

[0014] Figure 3 is a schematic diagram of the change curve of the ratio between the blood flow rate in the arterial line and the plasma flow rate in the plasma branch of the immune double plasma molecular adsorption system of the present application.

[0015] Main Components and Symbols Description:

[0016] 1. Arterial line; 2. Venous line; 3. Plasma branch; 4. Plasma separator; 5. Immune adsorption column; 6. Hemoperfusion cartridge; 7. First blood detection component; 8. Blood pump assembly; 9. Filtration pump assembly; 10. Second blood detection component; 11. First monitoring component; 12. Second monitoring component; 13. Third monitoring component; 14. First ion concentration detection component; 15. Second ion concentration detection component; 16. Venous chamber; 161. Input end of the venous chamber; 162. Output end of the venous chamber; 17. Third ion concentration detection component; 18. Emergency braking component; 19. Fourth monitoring component; 20. Fifth monitoring component; 21. Sixth monitoring component; 22. Heparin pump. Detailed Embodiments

[0017] The technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present application. Apparently, the described embodiments are some, but not all, of the embodiments of the present application. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present application without creative efforts shall fall within the protection scope of the present application.

[0018] Before elaborating on the embodiments of the present application in detail, the relevant technical content will be introduced first.

[0019] With the continuous development of blood purification technology, blood purification technology has evolved from the earliest hemodialysis treatment mode, hemofiltration treatment mode, hemodiafiltration treatment mode to various current blood purification modes. For example, current various blood purification modes also include: hemoperfusion treatment mode, plasma exchange treatment mode, single-pass plasma adsorption treatment mode, etc. Each blood purification mode is applicable to the treatment of specific clinical symptoms. For example, the hemoperfusion treatment mode is applicable to: the treatment of drug poisoning, kidney diseases, and immune system diseases, etc. in multiple fields; and for another example, the hemodialysis treatment mode can remove uremic toxins, waste, etc. from the blood, and the hemodialysis treatment mode is applicable to: multiple fields such as renal failure and renal insufficiency. After years of clinical treatment verification, blood purification technology has achieved good clinical treatment effects in various fields such as critical illnesses.

[0020] Based on the traditional blood purification modes, different blood purification modes are designed for different clinical symptoms, and these newly designed blood purification modes can achieve better clinical treatment effects in specific clinical symptoms.

[0021] For example, systemic lupus erythematosus is a chronic relapsing autoimmune disease involving multiple organs and systems, with multiple organs involved and a high mortality rate; due to the discovery of many autoantibodies, in the past 20 years, most researchers have been exploring the pathogenic role of a specific autoantibody in systemic lupus erythematosus. Especially in the late 1980s, more attention has been paid to anti-dsDNA, especially the pathogenic role of its idiotype 16 / 6. For the treatment of systemic lupus erythematosus, in addition to immunosuppressants and hormone treatment, traditional techniques can use the plasma exchange treatment mode and single-pass plasma adsorption treatment mode for blood purification treatment. However, the traditional single-pass plasma adsorption treatment mode has limited ability to adsorb pathogenic substances in the patient's blood, especially for multiple substances, it cannot achieve an ideal adsorption effect. Through IDPMAS, it can effectively combine broad-spectrum action and antigen-antibody specificity to increase the clearance ability of various substances such as anti-double-stranded DNA antibodies, anti-nuclear antibodies, and inflammatory mediators (such as IL-6, TNF-α, CRP) in the body, thereby achieving good treatment effects for patients with systemic lupus erythematosus.

[0022] However, IDPMAS belongs to a completely new blood purification mode. During the clinical promotion and application of IDPMAS, those skilled in the art cannot scientifically evaluate the blood purification effect of IDPMAS and cannot reasonably set the flow rate during the blood purification treatment process, thereby reducing the scope of clinical promotion and application of IDPMAS.

[0023] In the immune double plasma molecular adsorption system of the embodiment of the present application, when performing double plasma adsorption on the patient's blood, the blood pump assembly adjusts the blood flow in the arterial line, and the filtration pump assembly adjusts the plasma flow in the plasma branch, so that both the blood flow in the arterial line and the plasma flow in the plasma branch can be maintained in the optimal state, which can improve the effect of double plasma adsorption on the patient's blood; and evaluate the blood purification effect of the immune double plasma molecular adsorption system according to the ratio between the blood flow in the arterial line and the plasma flow in the plasma branch and the proportion of blood cells, thereby establishing a scientific evaluation standard for evaluating the treatment effect of the IDPMAS treatment mode, facilitating the promotion and application of the IDPMAS treatment mode, increasing the applicable range of IDPMAS, and being beneficial to improving the control effect of the IDPMAS treatment mode.

[0024] In order to better illustrate the specific implementation manner of IDPMAS in the embodiment of the present application, the following will be combined with Figure 1 to illustrate the working principle of IDPMAS.

[0025] The IDPMAS system includes: an arterial line 1, a venous line 2, a plasma separator 4, a plasma branch 3, an immunoadsorption column 5, and a hemoperfusion cartridge 6; the blood input end of the plasma separator 4 is connected to the arterial line 1, the blood output end of the plasma separator 4 is connected to the venous line 2, the first end of the plasma branch 3 is connected to the plasma output end of the plasma separator 4, and the second end of the plasma branch 3 is connected to the venous line 2; the immunoadsorption column 5 and the hemoperfusion cartridge 6 are connected in series in the plasma branch 3 in sequence.

[0026] Among them, the hemoperfusion cartridge 6 can adopt the HA330-II disposable hemoperfusion cartridge. The HA330-II disposable hemoperfusion cartridge has HA neutral macroporous resin inside. The HA neutral macroporous resin belongs to a broad-spectrum adsorbent, which has a macroporous structure and a large surface area, and adsorbs medium and large molecular toxins by van der Waals force and framework molecular sieve action. The immunoadsorption column 5 can adopt the DNA230 immunoadsorption column. The DNA230 immunoadsorption column has a good treatment effect on systemic lupus erythematosus. The DNA immunoadsorbent uses a ternary copolymer supermacroporous resin formed by polymerizing high molecules as raw materials, carbonizes and activates it to obtain a carbonized resin carrier, and then fixes DNA by the collodion coating method, so as to effectively adsorb anti-ds-DNA antibodies.

[0027] Specifically, after the arterial pipeline 1 outputs the patient's blood to the plasma separator 4, the plasma separator 4 contains a hollow fiber membrane inside. Using the membrane separation technology, the formed elements (blood cells) and plasma of the blood are separated. The plasma enters the plasma branch 3, and the blood cells enter the venous pipeline 2. The plasma flows in the plasma branch 3, and the plasma passes through the immunoadsorption column 5 and the hemoperfusion cartridge 6 in sequence. The two adsorbents, namely HA neutral macroporous resin and DNA immunosorbent, are used to jointly adsorb the plasma. Among them, the DNA immunosorbent uses its specific adsorption performance to selectively or specifically remove endogenous pathogenic factors in the patient's blood; the HA neutral macroporous adsorption resin can adsorb inflammatory mediators (such as IL-6, TNF-α, CRP), combining broad-spectrum action and antigen-antibody specificity, and the removal is more thorough, so as to achieve the purpose of purifying blood and treating diseases. Therefore, the immune dual plasma molecular adsorption system of the embodiment of the present application has excellent clinical treatment effects.

[0028] Please refer to Figure 1 , the immune dual plasma molecular adsorption system of the embodiment of the present application further includes: a first blood detection component 7, a blood pump component 8, a filtration pump component 9, a second blood detection component 10, and an evaluation component (not shown in the figure).

[0029] The first blood detection component 7 is arranged on the arterial pipeline 1 and is used to detect the plasma content of the blood in the arterial pipeline 1.

[0030] Specifically, the first blood detection component 7 can adopt a blood cell biochemical component analyzer in the traditional technology. The plasma content of human blood usually accounts for 55% - 60% of the blood; since everyone's physique is different, there will also be certain differences in the plasma content of each patient's blood. Therefore, when the arterial pipeline 1 transports blood, the first blood detection component 7 can accurately detect the plasma content of the blood in the arterial pipeline 1, and the operation state of the IDPMAS can be more accurately feedback-regulated according to the plasma content of the blood.

[0031] The blood pump component 8 is arranged on the arterial pipeline 1 and is used to adjust the blood flow in the arterial pipeline 1 according to the plasma content.

[0032] Specifically, the blood pump assembly 8 rotates to provide a driving force to the arterial line 1; according to the plasma content, the operating speed of the blood pump assembly 8 can be feedback-regulated to change the blood flow rate at the blood input end of the plasma separator 4, so that the plasma separator 4 can achieve the best plasma separation efficiency and prevent blood from clotting and blocking in the plasma separator 4. Generally, when the plasma content of the blood is larger (for example, the proportion of plasma in the blood is 60%), the more plasma separated by the plasma separator 4 per unit time. In this case, it is necessary to reduce the blood flow rate in the arterial line 1 to prevent the plasma separator 4 from separating too much plasma; when the plasma content of the blood is smaller (for example, the proportion of plasma in the blood is 55%), the less plasma separated by the plasma separator 4 per unit time. In this case, it is necessary to increase the blood flow rate in the arterial line 1 to prevent the plasma separator 4 from separating too little plasma and reducing the blood purification treatment efficiency of IDPMAS; Therefore, in the embodiment of the present application, the blood flow rate in the arterial line 1 is feedback-regulated according to the plasma content of the blood, so that the plasma separator 4 can achieve the best plasma separation effect.

[0033] The filtration pump assembly 9 is arranged on the plasma branch 3 and is used to adjust the plasma flow rate in the plasma branch 3 according to the blood chamber volume of the immunoadsorption column 5 and the blood chamber volume of the hemoperfusion cartridge 6.

[0034] Specifically, after the plasma separator 4 separates the patient's blood, the separated plasma is output to the plasma branch 3, and the plasma sequentially passes through the immunoadsorption column 5 and the hemoperfusion cartridge 6 to achieve dual plasma adsorption of the plasma. The plasma flow rate in the plasma branch 3 has a great influence on the adsorption efficiency of the immunoadsorption column 5 and the adsorption efficiency of the hemoperfusion cartridge 6. The blood chamber volume of the immunoadsorption column 5 may refer to the maximum blood volume that the immunoadsorption column 5 can access; the blood chamber volume of the hemoperfusion cartridge 6 may refer to the maximum blood volume that the hemoperfusion cartridge 6 can access. Therefore, in the embodiment of the present application, the plasma flow rate in the plasma branch 3 is feedback-regulated according to the blood chamber volumes of the immunoadsorption column 5 and the hemoperfusion cartridge 6 to ensure that the plasma volume accessed by the immunoadsorption column 5 and the plasma volume accessed by the hemoperfusion cartridge 6 can exactly achieve the best dual plasma adsorption effect on the patient's plasma. For example, when the blood chamber volumes of both the immunoadsorption column 5 and the hemoperfusion cartridge 6 are larger, the amount of adsorbent accommodated by both the immunoadsorption column 5 and the hemoperfusion cartridge 6 is larger, the blood volume that both the immunoadsorption column 5 and the hemoperfusion cartridge 6 can store is larger, and the adsorption performance for plasma is better. Therefore, it is necessary to increase the plasma flow rate in the plasma branch 3 to accelerate the adsorption efficiency of the plasma; when the blood chamber volumes of both the immunoadsorption column 5 and the hemoperfusion cartridge 6 are smaller, the amount of adsorbent accommodated by both the immunoadsorption column 5 and the hemoperfusion cartridge 6 is smaller, and the adsorption performance for plasma is lower. Therefore, it is necessary to reduce the plasma flow rate in the plasma branch 3 to prevent incomplete adsorption of the plasma by the immunoadsorption column 5 and the hemoperfusion cartridge 6. Therefore, in the embodiment of the present application, the plasma flow rate in the plasma branch 3 is feedback-regulated according to the blood chamber volumes of the immunoadsorption column 5 and the hemoperfusion cartridge 6 to achieve the best dual plasma adsorption performance for the plasma.

[0035] The second blood detection assembly 10 is arranged on the venous pipeline 2 and is used for detecting the proportion of blood cells in the purified blood output by the venous pipeline 2.

[0036] Specifically, the proportion of blood cells may refer to the volume ratio of blood cells in the human body's blood. After the immunoadsorption column 5 and the hemoperfusion cartridge 6 perform dual plasma adsorption on the patient's plasma, the adsorbed plasma and blood cells are mixed in the venous pipeline 2 to obtain purified blood. In the embodiment of the present application, the second blood detection assembly 10 detects the proportion of blood cells in the purified blood. Usually, the normal proportion of blood cells in the human body's blood is 45%, and the blood cells are red. The second blood detection assembly 10 in the embodiment of the present application can be implemented by a blood cell analyzer in the traditional technology. Its main principle is to use an image sensor to sample the images of the purified cells, and then the proportion of blood cells in the purified blood can be obtained according to the color difference of the sampled images. For example, the detected proportion of blood cells is 46%.

[0037] The evaluation component is used to evaluate the blood purification effect of the immune double plasma molecular adsorption system according to the ratio between the blood flow in the arterial pipeline 1 and the plasma flow in the plasma branch 3 and the proportion of blood cells.

[0038] Specifically, the ratio between the blood flow in the arterial pipeline 1 and the plasma flow in the plasma branch 3 can represent the separation efficiency of the plasma separator 4 for plasma. Under normal circumstances, the blood flow in the arterial pipeline 1 and the plasma flow in the plasma branch 3 have the same change trend. For example, the plasma flow in the plasma branch 3 will increase as the blood flow in the arterial pipeline 1 increases. The proportion of blood cells can represent: after double plasma adsorption of the patient's blood, the content of purified blood cells in the purified blood, and whether there are side effects on the patient's blood. Generally, only when both the ratio between the blood flow in the arterial pipeline 1 and the plasma flow in the plasma branch 3 and the proportion of blood cells are within the normal range, the immune double plasma molecular adsorption system can achieve the best blood purification effect and ensure the safety of the patient's blood purification treatment.

[0039] Exemplarily, the blood purification effect of the immune double plasma molecular adsorption system is divided into 4 states: insecurity, general, good, and excellent; the corresponding relationship among each state, the proportion of blood cells, and the ratio between the blood flow in the arterial pipeline 1 and the plasma flow in the plasma branch 3 can be expressed in the following text:

[0040] The proportion of blood cells is less than 43%, or the ratio between the blood flow in the arterial pipeline and the plasma flow in the plasma branch is less than 170%, and the blood purification effect of the immune double plasma molecular adsorption system is: insecure.

[0041] The proportion of blood cells is 43% - 44%, and the ratio between the blood flow in the arterial pipeline and the plasma flow in the plasma branch is 170% - 200%, and the blood purification effect of the immune double plasma molecular adsorption system is: general.

[0042] The proportion of blood cells is 44% - 45%, and the ratio between the blood flow in the arterial pipeline and the plasma flow in the plasma branch is 170% - 200%, and the blood purification effect of the immune double plasma molecular adsorption system is: excellent.

[0043] The proportion of blood cells is 45% - 46%, and the ratio between the blood flow in the arterial pipeline and the plasma flow in the plasma branch is 170% - 200%, and the blood purification effect of the immune double plasma molecular adsorption system is: good.

[0044] When the proportion of blood cells is greater than 46%, or when the ratio between the blood flow rate in the arterial line and the plasma flow rate in the plasma branch is greater than 200%, the blood purification effect of the immune double plasma molecular adsorption system is: unsafe.

[0045] Therefore, according to the ratio between the blood flow rate in the arterial line 1 and the plasma flow rate in the plasma branch 3 and the proportion of blood cells, the embodiments of the present application can scientifically and reasonably evaluate the blood purification effect of the immune double plasma molecular adsorption system, which is beneficial to improving the blood purification treatment effect of patients.

[0046] In one embodiment, the system further includes: a first monitoring component 11, a second monitoring component 12, a third monitoring component 13, and a first judgment component (not shown in the figure).

[0047] The first monitoring component 11 is disposed on the plasma branch 3 and near the blood input end of the immunoadsorption column 5 for monitoring the first plasma flow rate accessed by the immunoadsorption column 5. The second monitoring component 12 is disposed on the plasma branch 3 between the blood output end of the immunoadsorption column 5 and the blood input end of the hemoperfusion cartridge 6 for monitoring the second plasma flow rate accessed by the hemoperfusion cartridge 6. The third monitoring component 13 is disposed on the plasma branch 3 and near the blood output end of the hemoperfusion cartridge 6 for monitoring the third plasma flow rate output from the plasma branch 3. The first judgment component is configured to send a first alarm signal (such as a first audible and visual alarm signal) when it is determined that the first plasma flow rate, the second plasma flow rate, and the third plasma flow rate do not meet the following first condition. Wherein, the first condition is: the difference between the first plasma flow rate and the second plasma flow rate is greater than 0 and less than a first preset flow rate, and the difference between the second plasma flow rate and the third plasma flow rate is greater than 0 and less than a second preset flow rate.

[0048] In a mathematical expression, the first condition is: 0 < first plasma flow rate - second plasma flow rate < first preset flow rate; 0 < second plasma flow rate - third plasma flow rate < second preset flow rate; both the first preset flow rate and the second preset flow rate are preset values in advance.

[0049] Specifically, the detection principle of the first monitoring component 11, the second monitoring component 12, and the third monitoring component 13 for the flow rate in the pipeline can be: detecting the liquid flow rate in the pipeline through an ultrasonic sensor in traditional technology. When the plasma branch 3 accesses the separated plasma, the plasma sequentially passes through the immunosorbent column 5 and the hemoperfusion column 6. The adsorbent in the immunosorbent column 5 and the resin adsorbent in the hemoperfusion column 6 adsorb specific substances (such as inflammatory factors, etc.) in the plasma. Therefore, when the plasma passes through the immunosorbent column 5 and the hemoperfusion column 6, some substances are removed from the adsorbed plasma, and both the immunosorbent column 5 and the hemoperfusion column 6 have a certain buffering effect on the liquid flow. Then, under normal circumstances, the plasma flow rate output from the immunosorbent column 5 will be slightly smaller than the plasma flow rate accessed by the immunosorbent column 5, and the plasma flow rate output from the hemoperfusion column 6 will be slightly smaller than the plasma flow rate accessed by the hemoperfusion column 6. By comparing the differences among the first plasma flow rate, the second plasma flow rate, and the third plasma flow rate in the embodiments of the present application, it can be determined whether there is a failure when the plasma sequentially passes through the immunosorbent column 5 and the hemoperfusion column 6.

[0050] Taking the immunosorbent column 5 as an example, when the difference between the first plasma flow rate and the second plasma flow rate is within the range of (0, the first preset flow rate), it indicates that the plasma passing through the immunosorbent column 5 is in a normal state, and the immunosorbent column 5 has an adsorption effect on the plasma; when the difference between the second plasma flow rate and the third plasma flow rate is within the range of (0, the second preset flow rate), it indicates that the plasma passing through the hemoperfusion column 6 is in a normal state, and the hemoperfusion column 6 has an adsorption effect on the plasma. For example, when the first plasma flow rate - the second plasma flow rate > the first preset flow rate, it indicates that the plasma flow rate output from the immunosorbent column 5 is too low, and there may be a blockage failure in the flow process of the plasma in the immunosorbent column 5, or there may be a leakage failure in the immunosorbent column 5.

[0051] For the specific implementation manner of judging whether there is a failure in the plasma flow rate of the hemoperfusion column 6, it can refer to the specific implementation manner of judging whether there is a failure in the plasma flow rate of the immunosorbent column 5 above, and will not be elaborated here.

[0052] Therefore, in the embodiments of the present application, by detecting three plasma flow rates, it can be determined whether there is a failure in the plasma flow rate in the plasma branch 3, which can ensure the treatment safety of IDPMAS.

[0053] It should be noted that the first preset flow rate and the second preset flow rate are both preset values in advance, and these two values are both data obtained through multiple experiments. For example, the first preset flow rate: 20 ml / h, the second preset flow rate: 10 ml / h.

[0054] In one embodiment, the system further includes: a fourth determination component (not shown in the figure).

[0055] The fourth determination component is configured to issue a fourth alarm signal (such as a fourth audible and visual alarm signal) when the first plasma flow rate, the second plasma flow rate, and the third plasma flow rate satisfy the first condition, and it is detected that the weight change rate of the immunosorption column 5 is in a fault state, and / or it is detected that the weight change rate of the hemoperfusion cartridge 6 is in a fault state.

[0056] Specifically, when it is determined that the first plasma flow rate, the second plasma flow rate, and the third plasma flow rate satisfy the first condition, it indicates that the plasma flow rate in the plasma branch 3 is in a normal and safe state. In this case, the fourth determination component determines whether the dual plasma adsorption process of the blood is in a fault state based on the weight change rate of the immunosorption column 5 and the weight change rate of the hemoperfusion cartridge 6. As described above, the immunosorption column 5 has a certain blood chamber capacity, and the hemoperfusion cartridge 6 has a certain blood chamber capacity. Then, during the process of plasma flowing in the plasma branch 3, a certain volume of plasma will be stored in the immunosorption column 5, and a certain volume of plasma will be stored in the hemoperfusion cartridge 6; and the immunosorption column 5 will adsorb specific substances in the plasma, and the hemoperfusion cartridge 6 will adsorb specific substances in the plasma. Under normal circumstances, the weight of the immunosorption column 5 will remain unchanged (although the adsorbed specific substances will increase the weight of the immunosorption column 5, this increase in weight can be basically ignored); similarly, the weight of the hemoperfusion cartridge 6 will also remain unchanged; if it is detected that the weight change rate of the immunosorption column 5 and / or the hemoperfusion cartridge 6 is less than 0, it indicates that the adsorption process of the immunosorption column 5 and / or the hemoperfusion cartridge 6 to the plasma is in a fault state, and a fourth alarm signal is issued to prompt the user that a weight fault has occurred (the reason for this fault is likely to be that the housing of the immunosorption column 5 and / or the hemoperfusion cartridge 6 is damaged, resulting in liquid leakage, etc.).

[0057] Therefore, the embodiment of the present application combines the plasma flow rate in the plasma branch 3 and the weight change rate of the blood purification components (including: the immunosorption column 5 and the hemoperfusion cartridge 6) to double-detect the safety of plasma adsorption in the plasma branch 3, avoiding the problem of missed detection of faults in the plasma adsorption process in the plasma branch 3, and ensuring the safety of the IDPMAS treatment for patients.

[0058] In one embodiment, the system further includes: a first ion concentration detection component 14.

[0059] The first ion concentration detection component 14 is arranged on the plasma branch 3 and near the blood output end of the hemoperfusion cartridge 6, and is used to detect the first sodium ion concentration in the plasma output from the plasma branch 3.

[0060] Specifically, when the plasma passes through the plasma branch 3, after the plasma is subjected to double plasma adsorption by the immunoadsorption column 5 and the hemoperfusion cartridge 6, the first sodium ion concentration in the plasma after double plasma adsorption is detected by the first ion concentration detection component 14. The first sodium ion concentration can represent the conductivity of the plasma and the ion concentration of the plasma. When it is detected that the first sodium ion concentration is too low, it indicates that the plasma has electrolyte imbalance after double plasma adsorption. Therefore, by detecting the first sodium ion concentration, the sodium ion concentration in the plasma after double plasma adsorption can be monitored, and the safety of the plasma flow in the plasma branch 3 can be more comprehensively ensured.

[0061] In one embodiment, the system further includes a second ion concentration detection component 15 and a second judgment component (not shown in the figure).

[0062] The second ion concentration detection component 15 is arranged on the plasma branch 3 and on the pipeline between the plasma output end of the plasma separator 4 and the blood input end of the immunoadsorption column 5, and is used to detect the second sodium ion concentration in the plasma output from the plasma output end of the plasma separator 4.

[0063] Specifically, when the plasma separator 4 separates the patient's blood, the separated plasma is output through the plasma output end of the plasma separator 4, and the second sodium ion concentration in the separated plasma is detected by the second ion concentration detection component 15, so as to obtain the electrolyte level and conductivity of the separated plasma.

[0064] The second judgment component is used to send out a second alarm signal (such as a second audible and visual alarm signal) when it is judged that the first sodium ion concentration and the second sodium ion concentration do not meet the second condition. Wherein, the second condition is that the absolute value of the difference between the first sodium ion concentration and the second sodium ion concentration is less than a preset ion concentration.

[0065] In a mathematical expression, the second condition is: |first sodium ion concentration - second sodium ion concentration| < preset ion concentration; the preset ion concentration is a value preset in advance.

[0066] Specifically, under normal circumstances, when the plasma passes through the immunosorbent column 5 and the hemoperfusion cartridge 6 in sequence, the adsorbents of both the immunosorbent column 5 and the hemoperfusion cartridge 6 can only adsorb inflammatory mediators in the plasma (such as: IL-6, TNF-α, CRP), and will not cause a change in the sodium ion concentration in the plasma. That is: the second sodium ion concentration (the sodium ion concentration in the plasma accessed by the plasma branch 3) and the first sodium ion concentration (the sodium ion concentration in the plasma output by the plasma branch 3) will not differ too much; therefore, when the first sodium ion concentration and the second sodium ion concentration do not meet the second condition, when the plasma passes through the immunosorbent column 5 and the hemoperfusion cartridge 6, the adsorbent reacts with the plasma to produce some allergic chemical reactions or the adsorbent abnormally adsorbs sodium ions in the plasma, resulting in a large fluctuation in the sodium ion concentration in the plasma after double plasma adsorption, and a second alarm signal is sent. When the user obtains the second alarm signal, they can know that there is a malfunction in the plasma in the plasma branch 3.

[0067] It should be noted that, |the first sodium ion concentration - the second sodium ion concentration| can represent: the absolute value of the difference between the first sodium ion concentration and the second sodium ion concentration. For example, the first sodium ion concentration is 30 mmol / L, the second sodium ion concentration is 31 mmol / L, and the preset ion concentration is preset to: 1.5 mmol / L. Therefore: |the first sodium ion concentration - the second sodium ion concentration| = |30 mmol / L - 31 mmol / L| = 1 mmol / L < 1.5 mmol / L, which meets the second condition and no second alarm signal needs to be sent.

[0068] It should be noted that the detection principle of the first ion concentration detection component and the second ion concentration detection component for the sodium ion concentration in the embodiments of the present application can be: the sodium ion concentration of the plasma in the pipeline can be detected in time through the sodium ion detection electrode in the traditional technology.

[0069] In one embodiment, the system further includes: a drip chamber 16.

[0070] The drip chamber 16 is connected in series to the venous line 2, and the second end of the plasma branch 3 is connected to the input end 161 of the drip chamber 16.

[0071] Among them, the drip chamber 16 has an input end 161 and an output end 162. The input end 161 of the drip chamber 16 can access liquid, and the output end 162 of the drip chamber 16 can output liquid. The drip chamber 16 is one of the essential components of the IDPMAS. The drip chamber 16 is connected in series to the venous line 2, and the drip chamber 16 can buffer the blood flow rate and remove air bubbles in the blood on the venous line 2. Such as Figure 1As shown, the second end of the plasma branch 3 is connected to the input end 161 of the venous chamber 16. When the plasma separator 4 separates blood into blood cells and plasma, the venous line 2 outputs the blood cells to the venous chamber 16, and the plasma branch 3 outputs the plasma after double plasma adsorption to the venous chamber 16. After the blood cells and the plasma after double plasma adsorption are mixed in the venous chamber 16, the purified blood is obtained, and then the purified blood is transfused back to the patient's vein through the venous line 2.

[0072] In one embodiment, the system further includes: a third ion concentration detection component 17 and a third judgment component (not shown in the figure).

[0073] The third ion concentration detection component 17 is arranged on the venous line 2 and on the line connected to the output end 162 of the venous chamber 16, and is used to detect the third sodium ion concentration in the blood output from the output end 162 of the venous chamber 16.

[0074] The third judgment component is used to issue a third alarm signal (such as a third audible and visual alarm signal) when it is judged that the third sodium ion concentration does not meet the third condition; wherein, the third condition is: the third sodium ion concentration is greater than the lowest safe concentration and less than the highest safe concentration.

[0075] In a mathematical expression, the third condition is: the lowest safe concentration < the third sodium ion concentration < the highest safe concentration; wherein, the lowest safe concentration and the highest safe concentration are preset values.

[0076] When the plasma after double plasma adsorption and the blood cells are mixed in the venous chamber 16, the third sodium ion concentration in the blood output from the output end 162 of the venous chamber 16 is detected. According to the third sodium ion concentration, it can be judged whether the sodium ion concentration in the purified blood meets the normal sodium ion concentration in human blood; for example, when the third sodium ion concentration ≤ the lowest safe concentration, the purified blood will cause the patient to have hyponatremia; when the third sodium ion concentration ≥ the highest safe concentration, the purified blood will cause the patient to have hypernatremia; when the third judgment component issues a third alarm signal, the user obtains the third alarm signal and can know that there is a malfunction in the IDPMAS treatment process of the patient, and the user can timely handle the malfunction problem in the IDPMAS treatment process.

[0077] In one embodiment, the system further includes: an emergency braking component 18.

[0078] The emergency braking component 18 is used to output an emergency braking signal when it detects that the blood flow in the arterial line 1 is less than or equal to the lowest blood flow, and the lowest blood flow is greater than 0. At this time, the filtration pump component 9 is further used to control the plasma flow in the plasma branch 3 to be 0 according to the emergency braking signal.

[0079] Wherein, the minimum blood flow rate is a preset value, and the minimum blood flow rate is greater than 0.

[0080] Specifically, the emergency braking assembly 18 can detect the magnitude relationship between the blood flow rate in the arterial line 1 and the minimum blood flow rate; since the arterial line 1 outputs blood to the plasma separator 4, and then the hollow fiber membrane in the plasma separator 4 separates the blood, separated plasma can be obtained; then the filtration pump assembly 9 rotates to provide a driving force to the plasma branch line 3 to output the separated plasma into the plasma branch line 3; therefore, when the blood flow rate in the arterial line 1 is too low (that is, less than or equal to the minimum blood flow rate), if the filtration pump assembly 9 still keeps running, the amount of plasma separated by the plasma separator 4 is too small, which will cause the filtration pump assembly 9 to run idly. Even if the running speed of the filtration pump assembly 9 is increased, the plasma flow rate in the plasma branch line 3 will not change, and this idling phenomenon will also cause the plasma separator 4 to malfunction (such as membrane rupture failure, etc.). Therefore, in the embodiment of the present application, by detecting the blood flow rate in the arterial line 1, it is judged whether the condition for stopping the plasma flow in the plasma branch line 3 is met; for example, when the blood flow rate in the arterial line 1 is less than or equal to the minimum blood flow rate, the filtration pump assembly 9 is controlled to automatically stop to prevent the filtration pump assembly 9 from running idly.

[0081] It should be noted that the minimum blood flow rate in the embodiment of the present application is greater than 0, so it can be ensured that the filtration pump assembly 9 will stop directly when the blood flow rate in the arterial line 1 is small enough, rather than stopping when the blood flow rate must be 0; for example, if the blood flow rate in the arterial line 1 gradually decreases to 0, during the process of the blood flow rate in the arterial line 1 decreasing, the blood flow rate will gradually decrease and it takes a certain amount of time. When the emergency braking assembly 18 detects that the blood flow rate is less than or equal to the minimum blood flow rate (for example, the minimum blood flow rate is 3 ml / min), it will control the filtration pump assembly 9 to stop in advance, ensuring the safety of plasma separation of the plasma separator 4.

[0082] In one embodiment, the system further includes: a starting assembly (not shown in the figure).

[0083] The starting assembly is used to output a starting signal when it detects that the blood flow rate in the arterial line 1 is greater than the minimum blood flow rate; at this time, the filtration pump assembly 9 is further used to control the plasma flow in the plasma branch line 3 according to the starting signal, and adjust the plasma flow rate in the plasma branch line 3 according to the blood chamber volume of the immunoadsorption column 5 and the blood chamber volume of the hemoperfusion cartridge 6.

[0084] As described above, the minimum blood flow represents the minimum blood flow in the arterial line 1 when the filtration pump assembly 9 can operate; for example, when the IDPMAS is started, the blood flow in the arterial line 1 rises from 0. When the blood flow in the arterial line 1 rises to the minimum blood flow, the filtration pump assembly 9 controls the plasma in the plasma branch 3 to start flowing, and the separated plasma is subjected to dual plasma molecular adsorption through the plasma branch 3, ensuring the safety of the plasma separator 4 and the safety of the patient's IDPMAS treatment; it avoids the problem that when the blood flow in the arterial line 1 is too small, the operation of the filtration pump assembly 9 causes a risk of membrane rupture in the plasma separator 4 and low safety of the patient's blood purification treatment.

[0085] In one embodiment, the system further includes: a display component (not shown in the figure).

[0086] The display component is used to display the change curve of the plasma flow in the plasma branch 3, the change curve of the blood flow in the arterial line 1, and the change curve of the ratio between the blood flow in the arterial line 1 and the plasma flow in the plasma branch 3.

[0087] Figure 2 Shows the change curve of the plasma flow in the plasma branch and the change curve of the blood flow in the arterial line; Figure 3 Shows the change curve of the ratio between the blood flow in the arterial line and the plasma flow in the plasma branch; Through Figure 2 and Figure 3 The change of the numerical value over time can be obtained from the curves of these two, and the blood purification safety state of the patient during the IDPMAS treatment can be obtained according to the change of the numerical value. The user can directly see the change curve, and then monitor the blood purification state of the patient in real time. The IDPMAS in the embodiment of the present application has higher human-computer interaction performance.

[0088] In one embodiment, the system further includes: a wireless communication component (not shown in the figure).

[0089] The wireless communication component is used to send the blood cell ratio to the mobile terminal.

[0090] Optionally, the mobile terminal includes but is not limited to a desktop computer, etc.; after the second blood detection component 10 detects the blood cell ratio, the user can remotely view the blood cell ratio on the mobile terminal, providing higher convenience for the user. Especially when this solution is applied in a hospital environment, medical staff can directly view the blood cell ratio of the patient during the IDPMAS treatment in the office, and judge whether there are side effects or abnormal phenomena in the patient's blood purification treatment process according to the blood cell ratio, simplifying the IDPMAS control operation steps of the patient.

[0091] In one embodiment, the system further includes: a fourth monitoring component 19, a fifth monitoring component 20, and a fifth judgment component (not shown in the figure).

[0092] The fourth monitoring component 19 is disposed on the arterial line 1 for detecting a first blood flow rate in the arterial line 1. The fifth monitoring component 20 is disposed on the venous line 2 and on the venous line 2 connected to the output end 162 of the venous pot 16 for detecting a second blood flow rate in the venous line 2. The fifth judgment component is configured to issue a fifth alarm signal (such as a fifth audible and visual alarm signal) when it is determined that the first blood flow rate and the second blood flow rate do not meet the fourth condition; wherein, the fourth condition is: the absolute value of the difference between the first blood flow rate and the second blood flow rate is less than a third preset flow rate.

[0093] In a mathematical expression, the fourth condition is: |First blood flow rate - Second blood flow rate| < Third preset flow rate; wherein, the third preset flow rate is a pre-set value.

[0094] Specifically, the first blood flow rate may represent the blood flow rate accessed by the arterial line 1, and the second blood flow rate may represent: the blood flow rate output from the venous line 2 into the patient's body. Under normal circumstances, after the blood passes through double plasma adsorption, and the heparin pump 22 will output anticoagulant into the arterial line 1 during the IDPMAS treatment process (wherein, the node where the heparin pump 22 adds anticoagulant is on the pipeline between the fourth monitoring component 19 and the blood input end of the plasma separator 4), then the difference between the first blood flow rate and the second blood flow rate will be within a certain range, that is, the first blood flow rate and the second blood flow rate meet the fourth condition.

[0095] On the contrary, if the second blood flow rate suddenly drops significantly and does not meet the fourth condition, it indicates that there is a fault in the blood flow in the pipeline (the reasons for the fault may be: liquid leakage, blood coagulation, blockage, etc.). By issuing the fifth alarm signal, the user can be prompted that there is a fault in the blood flow process in the pipeline. For example, the third preset flow rate is pre-set to: 10 ml / min, the first blood flow rate is: 120 ml / min, and the second blood flow rate is: 105 ml / min, then |First blood flow rate - Second blood flow rate| = |120 ml / min - 105 ml / min| = 15 ml / min > 10 ml / min, and at this time, the fifth alarm signal is issued.

[0096] In one embodiment, the system further includes: a sixth monitoring component 21 and a sixth judgment component (not shown in the figure).

[0097] The sixth monitoring component 21 is disposed on the venous line 2, and is disposed on the venous line 2 between the blood output end of the plasma separator 4 and the input end 161 of the venous chamber 16, and is used to detect the blood cell flow rate in the venous line 2. The sixth judgment component is configured to issue a sixth alarm signal when it is determined that the blood cell flow rate, the third plasma flow rate, and the second blood flow rate do not meet the fifth condition; wherein, the fifth condition is that the value after adding the blood cell flow rate, the third plasma flow rate, and subtracting the second blood flow rate is greater than a fourth preset flow rate and less than a fifth preset flow rate.

[0098] In a mathematical expression, the fifth condition is:

[0099] Fourth preset flow rate < blood cell flow rate + third plasma flow rate - second blood flow rate < fifth preset flow rate; wherein, the fourth preset flow rate and the fifth preset flow rate are preset values in advance.

[0100] Specifically, when the blood output end of the plasma separator 4 outputs separated blood cells, the blood cell flow rate in the venous line 2 can be detected by the sixth monitoring component 21; referring to Figure 2 , the blood cells and the plasma after double plasma adsorption are mixed in the venous chamber 16 to obtain purified blood, and then the purified blood is transfused back to the patient's body through the output end 162 of the venous chamber 16; during the blood purification treatment process, the liquid level in the venous chamber 16 needs to be maintained in a stable state, and the total volume of the liquid connected to the input end 161 of the venous chamber 16 and the total volume of the liquid output from the output end 162 of the venous chamber 16 need to be equal. If the blood cell flow rate, the third plasma flow rate, and the second blood flow rate meet the fifth condition, it means that the liquid in the venous chamber 16 is in a safe flow state; when the fifth condition is not met, it means that the liquid in the venous chamber 16 is in a faulty flow state, and then a sixth alarm signal is issued; when the user obtains the sixth alarm signal, the user knows that the liquid in the venous chamber 16 is in a faulty flow state, and thus the user can timely handle the faulty flow state of the venous chamber 16, ensuring the safety of the blood purification treatment.

[0101] Exemplarily, the fourth preset flow rate can be preset in advance as: -10 ml / min, the fifth preset flow rate can be preset in advance as: 10 ml / min, the blood cell flow rate is: 56 ml / min, the third plasma flow rate is: 68 ml / min, and the second blood flow rate is: 110 ml / min; blood cell flow rate + third plasma flow rate - second blood flow rate = 56 ml / min + 68 ml / min - 110 ml / min = 14 ml / min > 10 ml / min, then the fifth condition is not satisfied, and a sixth alarm signal is issued to prompt that the liquid in the venous chamber 16 is in a faulty flow state (the reason for the liquid in the venous chamber 16 to be in a faulty state may be that the blood accumulated in the venous chamber 16 coagulates, resulting in a significant decrease in the blood flow rate output from the output end 162 of the venous chamber 16).

[0102] It should be noted that the fourth preset flow rate and the fifth preset flow rate belong to the allowable liquid flow rate fluctuation error. For example, due to a slight fluctuation in the liquid level in the venous chamber 16, it will also cause the calculation result of the blood cell flow rate + third plasma flow rate - second blood flow rate to fluctuate; the calculation result fluctuations caused by the liquid level fluctuation in the venous chamber 16 will all be within the interval of (the fourth preset flow rate, the fifth preset flow rate). Therefore, according to the relationship among the blood cell flow rate, the third plasma flow rate, and the second blood flow rate in the embodiments of the present application, it can accurately determine whether the liquid in the venous chamber 16 is in a faulty flow state, improving the blood flow safety during the IDPMAS treatment process.

[0103] It should be understood that the terms used in the specification of the present application are only for the purpose of describing specific embodiments and are not intended to limit the present application.

[0104] It should also be understood that the term "and / or" used in the specification and the appended claims of the present application refers to any combination and all possible combinations of one or more of the associated listed items, and includes these combinations.

[0105] As described above, the above are only specific embodiments of the present application, but the protection scope of the present application is not limited thereto. Any person skilled in the art within the technical scope disclosed in the present application can easily think of various equivalent modifications or substitutions, and these modifications or substitutions should all be covered by the protection scope of the present application. Therefore, the protection scope of the present application should be subject to the protection scope of the claims.

Claims

1. An immunoadsorption double plasma molecular adsorption system, characterized in that The system includes: an arterial line, a venous line, a plasma separator, a plasma branch, an immunoadsorption column, and a hemoperfusion cartridge; the blood input end of the plasma separator is connected to the arterial line, the blood output end of the plasma separator is connected to the venous line, the first end of the plasma branch is connected to the plasma output end of the plasma separator, and the second end of the plasma branch is connected to the venous line; the immunoadsorption column and the hemoperfusion cartridge are connected in series in the plasma branch in sequence; the system further includes: A first blood detection component, arranged on the arterial line, for detecting the plasma content in the blood in the arterial line; A blood pump component, arranged on the arterial line, for adjusting the blood flow rate in the arterial line according to the plasma content; A filtration pump component, arranged on the plasma branch, for adjusting the plasma flow rate in the plasma branch according to the blood chamber volume of the immunoadsorption column and the blood chamber volume of the hemoperfusion cartridge; A second blood detection component, arranged on the venous line, for detecting the proportion of blood cells in the purified blood output from the venous line; An evaluation component, for evaluating the blood purification effect of the immune double plasma molecular adsorption system according to the ratio between the blood flow rate in the arterial line and the plasma flow rate in the plasma branch and the proportion of blood cells; A first monitoring component, arranged on the plasma branch near the blood input end of the immunoadsorption column, for monitoring the first plasma flow rate accessed by the immunoadsorption column; A second monitoring component, arranged on the plasma branch between the blood output end of the immunoadsorption column and the blood input end of the hemoperfusion cartridge, for monitoring the second plasma flow rate accessed by the hemoperfusion cartridge; A third monitoring component, arranged on the plasma branch near the blood output end of the hemoperfusion cartridge, for monitoring the third plasma flow rate output from the plasma branch; A fourth judgment component, for when the first plasma flow rate, the second plasma flow rate, and the third plasma flow rate meet the first condition, and it is detected that the weight change rate of the immunoadsorption column is in a failure state, and / or, it is detected that the weight change rate of the hemoperfusion cartridge is in a failure state, then a fourth alarm signal is issued; Wherein, the first condition is: the difference between the first plasma flow rate and the second plasma flow rate is greater than 0 and less than a first preset flow rate, and the difference between the second plasma flow rate and the third plasma flow rate is greater than 0 and less than a second preset flow rate.

2. The system according to claim 1, characterized in that, The system further includes: A first judgment component, for when it is judged that the first plasma flow rate, the second plasma flow rate, and the third plasma flow rate do not meet the first condition, then a first alarm signal is issued.

3. The system according to claim 1, wherein The system further includes: A first ion concentration detection component, arranged on the plasma branch near the blood output end of the hemoperfusion cartridge, for detecting the first sodium ion concentration in the plasma output from the plasma branch; 4. The system according to claim 3, wherein The system further includes: A second ion concentration detection component, arranged on the plasma branch between the plasma output end of the plasma separator and the blood input end of the immunoadsorption column, for detecting the second sodium ion concentration in the plasma output from the plasma output end of the plasma separator; A second judgment component, configured to send a second alarm signal when it is determined that the first sodium ion concentration and the second sodium ion concentration do not meet the second condition; Wherein, the second condition is that the absolute value of the difference between the first sodium ion concentration and the second sodium ion concentration is less than a preset ion concentration.

5. The system according to claim 4, wherein The system further includes: An intravenous drip chamber, connected in series to the intravenous pipeline, and the second end of the plasma branch is connected to the input end of the intravenous drip chamber; A third ion concentration detection component, arranged on the intravenous pipeline connected to the output end of the intravenous drip chamber, for detecting the third sodium ion concentration in the blood output from the output end of the intravenous drip chamber; A third judgment component, configured to send a third alarm signal when it is determined that the third sodium ion concentration does not meet the third condition; Wherein, the third condition is that the third sodium ion concentration is greater than the lowest safe concentration and less than the highest safe concentration.

6. The system according to claim 1, characterized in that, The system further includes: An emergency braking component, configured to output an emergency braking signal when it is detected that the blood flow rate in the arterial pipeline is less than or equal to the lowest blood flow rate, and the lowest blood flow rate is greater than 0; The filtration pump assembly is further configured to control the plasma flow rate in the plasma branch to be 0 according to the emergency braking signal.

7. The system according to claim 6, characterized in that, The system further includes: A start-up component, configured to output a start-up signal when it is detected that the blood flow rate in the arterial pipeline is greater than the lowest blood flow rate; The filtration pump assembly is further configured to control the plasma flow in the plasma branch according to the start-up signal, and adjust the plasma flow rate in the plasma branch according to the blood chamber volume of the immunoadsorption column and the blood chamber volume of the hemoperfusion cartridge.

8. The system according to claim 1, wherein The system further includes: A display component, configured to display the change curve of the plasma flow rate in the plasma branch, the change curve of the blood flow rate in the arterial pipeline, and the change curve of the ratio between the blood flow rate in the arterial pipeline and the plasma flow rate in the plasma branch; And / or The system further includes: A wireless communication component, configured to send the proportion of blood cells to a mobile terminal.

9. The system according to claim 1, wherein The system further includes: An intravenous drip chamber, connected in series to the intravenous pipeline, and the second end of the plasma branch is connected to the input end of the intravenous drip chamber; A fourth monitoring component, arranged on the arterial pipeline, for detecting the first blood flow rate in the arterial pipeline; A fifth monitoring component, arranged on the intravenous pipeline connected to the output end of the intravenous drip chamber, for detecting the second blood flow rate in the intravenous pipeline; A fifth judgment component, configured to send a fifth alarm signal when it is determined that the first blood flow rate and the second blood flow rate do not meet the fourth condition; Wherein, the fourth condition is that the absolute value of the difference between the first blood flow rate and the second blood flow rate is less than a third preset flow rate.

10. The system according to claim 9, wherein The system further includes: A sixth monitoring component, arranged on the intravenous pipeline between the blood output end of the plasma separator and the input end of the intravenous drip chamber, for detecting the blood cell flow rate in the intravenous pipeline; A sixth judgment component, configured to send a sixth alarm signal when it is determined that the blood cell flow rate, the third plasma flow rate, and the second blood flow rate do not meet the fifth condition; Wherein, the fifth condition is that the value obtained by adding the blood cell flow rate, adding the third plasma flow rate, and subtracting the second blood flow rate is greater than a fourth preset flow rate and less than a fifth preset flow rate.

Images